- BiomX will generate metagenomic data of gut microbiome samples obtained from IBD patients with the focus of identifying biomarkers using the XMarker platform
- Boehringer Ingelheim gets an option to negotiate an exclusive right to biomarkers discovered under the collaboration.
- The XMarker platform supports the phage therapy for IBD, BX002, via analysis of real-world metagenomic patient data. The BiomX will continue to advance the therapy in P-Ia study independently, which is expected to be initiated in Q3’20
Click here to read full press release/ article | Ref: PRNewswire | Image: Downriver Gastroenterology, PC